Philip Jones

This inventor holds 82 USPTO granted patents and 26 published patent applications, plus 3 CIPO patents and 18 EPO patents, primarily in Heterocyclic Inhibitors (CPC class A61K45-06). Top assignees: The University of Texas System, Merck Sharp + Dohme Corp., Chempartner Corporation. Active years: 2002-2026.

USPTO Granted Patents = 82 (Patent Applications = 26)

% Patents Active = 74.4

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 18 (Patent Applications = 29)

Average Co-Inventor Count = 5.8

ph-index = 9

Forward Citations = 357(Granted Patents)

Forward Citations (Not Self Cited) = 220(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Bishops Stortford, GB (2002 - 2005)
Bishop Stortford, GB (2006)
Pomezia, IT (2005 - 2013)
Rome, IT (2011 - 2013)
Brookline, MA (US) (2013)
Houston, TX (US) (2013 - 2024)

Company Filing History:

50 out of 5,627

The University of Texas System

patents

16 out of 2,405

Merck Sharp + Dohme Corp.

patents

7 out of 7

Chempartner Corporation

patents

4. 5 out of 47

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

patents

5. 3 out of 11

Instituto Di Ricerche Di Biologia Molecolare P. Angeletti

Golgi Neurosciences S.r.l.

patents

8. 2 out of 4

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

patent

12. 1 out of 1

Istituto De Ricerche Di Biologia Molecolare P. Angeletti Spa.

patent

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Imidazopiperazine

CX3CR1 Receptor Agonists

PTPN11 Inhibitors

GLS1 Inhibitors

Cyclic Dinucleotides

Heterocyclic Modulators

ATR Kinase

Dual Leucine Zipper Kinase

Transcription Activating Proteins

Indoleamine 2,3-Dioxygenase

Protein Arginine Methyltransferases

Bicyclic Compounds

82 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559497 - Imidazopiperazine inhibitors of transcription activating proteins (2026-02-24),

2. 12540139 - Imidazopiperazine inhibitors of transcription activating proteins (2026-02-03),

3. 12258337 - Bicyclic CX3CR1 receptor agonists (2025-03-25),

4. 12252480 - Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide (2025-03-18),

5. 12186324 - Imidazopiperazine inhibitors of transcription activating proteins (2025-01-07),

6. 12036231 - Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling (2024-07-16),

7. 11958849 - GLS1 inhibitors for treating disease (2024-04-16),

8. 11958839 - Bicyclic CX3CR1 receptor agonists (2024-04-16),

9. 11945815 - PTPN11 inhibitors (2024-04-02),

10. 11932643 - Substituted heterocyclic inhibitors of PTPN11 (2024-03-19),

11. 11840536 - Heterocyclic inhibitors of PTPN11 (2023-12-12),

12. 11725008 - Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases (2023-08-15),

13. 11713313 - GLS1 inhibitors for treating disease (2023-08-01),

14. 11603365 - Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide (2023-03-14),

15. 11560366 - Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease (2023-01-24),

Title: Philip Jones: Innovator in Pharmaceutical Research and Patent Holder

Introduction

Philip Jones, based in Houston, TX, is a distinguished inventor with a remarkable portfolio of 78 patents. His contributions primarily focus on pharmaceutical innovations that address various health conditions, showcasing his deep commitment to advancing medical science.

Latest Patents

Among his recent patents, Philip has developed imidazopiperazine inhibitors of transcription activating proteins. This groundbreaking work involves heterocyclic compounds that target proteins such as CBP and P300, offering potential treatments for proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases. Additionally, he has patented cyclic dinucleotides emerging as agonists of stimulator of interferon gene dependent signaling. This innovation provides new cyclic dinucleotide compounds for pharmaceutical applications aimed at treating diseases, while also enhancing immune response and serving as anti-viral agents and vaccine adjuvants.

Career Highlights

Philip Jones has had a significant career, working with prestigious organizations such as the University of Texas System and Merck Sharp & Dohme Corporation. His roles at these institutions have allowed him to push the boundaries of pharmaceutical research and innovation, leading to numerous patents that contribute to healthcare advancements.

Collaborations

Throughout his career, Philip has collaborated with talented individuals, including Maria Emilia Di Francesco and Jason Cross. These partnerships have fostered an environment of innovation and creativity, allowing for the development of transformative medical solutions.

Conclusion

With an impressive collection of patents and a dedication to pharmaceutical research, Philip Jones continues to make substantial contributions to the field of medicine. His innovative spirit and collaborative efforts underline the importance of scientific advancement in addressing complex health issues.